199,233 Shares in Maplight Therapeutics, Inc. $MPLT Purchased by Board of Trustees of The Leland Stanford Junior University

Board of Trustees of The Leland Stanford Junior University acquired a new position in Maplight Therapeutics, Inc. (NASDAQ:MPLT) in the 4th quarter, Holdings Channel reports. The institutional investor acquired 199,233 shares of the company’s stock, valued at approximately $3,500,000. Maplight Therapeutics accounts for 0.7% of Board of Trustees of The Leland Stanford Junior University’s holdings, making the stock its 7th biggest position.

Several other institutional investors have also bought and sold shares of the stock. Goldman Sachs Group Inc. acquired a new stake in Maplight Therapeutics in the fourth quarter worth about $34,026,000. Nan Fung Group Holdings Ltd acquired a new stake in Maplight Therapeutics in the fourth quarter worth about $17,060,000. Sanofi acquired a new stake in Maplight Therapeutics in the fourth quarter worth about $16,020,000. Pivotal bioVenture Partners Investment Advisor LLC acquired a new stake in Maplight Therapeutics in the fourth quarter worth about $10,743,000. Finally, Velan Capital Investment Management LP acquired a new stake in Maplight Therapeutics in the fourth quarter worth about $9,174,000.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Stifel Nicolaus upped their price objective on shares of Maplight Therapeutics from $28.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, June 1st. Craig Hallum assumed coverage on shares of Maplight Therapeutics in a report on Thursday, May 21st. They issued a “buy” rating and a $43.00 price objective for the company. UBS Group assumed coverage on shares of Maplight Therapeutics in a report on Tuesday, May 26th. They issued a “buy” rating and a $48.00 price objective for the company. TD Cowen assumed coverage on shares of Maplight Therapeutics in a report on Tuesday, April 7th. They issued a “buy” rating for the company. Finally, Wall Street Zen downgraded shares of Maplight Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Three equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $37.78.

Insider Buying and Selling

In other news, insider Erin Pennock Foff sold 24,052 shares of the company’s stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $28.76, for a total value of $691,735.52. Following the transaction, the insider owned 350,497 shares in the company, valued at $10,080,293.72. This represents a 6.42% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider James Woodruff Lillie sold 24,811 shares of the company’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $28.76, for a total value of $713,564.36. Following the completion of the transaction, the insider owned 243,450 shares in the company, valued at $7,001,622. This represents a 9.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 495,244 shares of company stock worth $14,079,461 over the last ninety days. 3.80% of the stock is currently owned by corporate insiders.

Maplight Therapeutics Trading Up 0.8%

NASDAQ MPLT opened at $27.96 on Tuesday. The stock’s 50-day moving average price is $28.44 and its two-hundred day moving average price is $21.63. The company has a market cap of $1.19 billion and a PE ratio of -0.68. Maplight Therapeutics, Inc. has a 1 year low of $12.24 and a 1 year high of $33.28.

Maplight Therapeutics (NASDAQ:MPLT) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($1.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.91) by ($0.43). Research analysts forecast that Maplight Therapeutics, Inc. will post -5.04 EPS for the current fiscal year.

Maplight Therapeutics Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.